Full Press Release Details
Bio Solutions Secures Key U.S. Patent, Strengthening IP Protection Ahead of Planned 2025 Market Entry
6th U.S. patent adds to comprehensive IP portfolio protecting its unique drug screening technology
protection strengthens Company's competitive position as it prepares for planned entry into multi-billion dollar U.S. market in
YORK, March 26, 2025 - Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical
technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that the Company has been granted a
patent in the United States (U.S.) relating to its Intelligent Fingerprinting Drug Screening Cartridge. This is the Company's sixth
active patent to be granted in the U.S., strengthening the protection of its unique and proprietary drug screening technology.
Patent No: 12259385, relates to the proprietary lateral flow test strip inside the Company's Drug Screening Cartridge and ensures
that all current and future screening cartridge products developed by INBS are protected under U.S. intellectual property law. The patent
is fundamental to the Company's testing system, which uses lateral flow technology to detect drugs in fingerprint sweat. This latest
patent enhances the Company's U.S. intellectual property portfolio, which also includes patents covering INBS' Sample Collection
Cartridge, cartridge housing and buffer clip design.
intellectual property landscape for lateral flow devices in the U.S. is mature, making the grant of this patent a strong validation of
our innovative technology," said Harry Simeonidis, President and CEO at Intelligent Bio Solutions. "The U.S. is a key market
for us, and securing broad intellectual property protection strengthens our competitive position as we plan for entry into this multi-billion
dollar market in 2025."
Company's Intelligent Fingerprinting Drug Testing Solution uses fingerprint sweat analysis to detect common drugs of abuse, an
area of growing demand across multiple industries who want to ensure their employees are safe to work. The unique, non-invasive solution
addresses the challenges faced by safety-sensitive industries, streamlines drug testing processes, and provides an alternative method
that supports employee well-being and compliance. With recent FDA 510(k) submission in December 2024 and plans to enter the U.S. market
in 2025, INBS is well-positioned to leverage the rapidly expanding global drug screening market.
Intelligent Bio Solutions Inc.
Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company delivering intelligent, rapid, non-invasive testing solutions. The
Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat
analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the
test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis.
With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical
industries. The Company's current customer segments outside the US include construction, manufacturing and engineering, transport
and logistics firms, drug treatment organizations, and coroners.
more information, visit: http://www.ibs.inc
of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section
21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties.
Forward-looking statements in this press release include, without limitation, Intelligent Bio Solutions Inc.'s ability to successfully
develop and commercialize its drug and diagnostic tests, realize commercial benefit from its partnerships and collaborations, and secure
regulatory approvals, among others. Although Intelligent Bio Solutions Inc. believes that the expectations reflected in such forward-looking
statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or
implied by such forward-looking statements. Intelligent Bio Solutions Inc. has attempted to identify forward-looking statements by terminology,
including "believes," "estimates," "anticipates," "expects," "plans," "projects,"
"intends," "potential," "may," "could," "might," "will," "should,"
"approximately" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements.
These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, included in Intelligent
Bio Solutions' public filings filed with the Securities and Exchange Commission. Any forward-looking statements contained in this
release speak only as of its date. Intelligent Bio Solutions undertakes no obligation to update any forward-looking statements contained
in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.
Pinto, Managing Director
Strategic Communications